Table 3 Comparisons of VAS between curcumin supplement and placebo

(a) VAS preexercise

Nicol LM

17

0

0

17

0

0

Tanabe Y

14

0.68

0.91

14

0.34

0.57

McFarlin BK

14

0.16

0.53

14

0.21

0.63

Naknhostin-Roohi B

10

5.93

0.19

10

5.93

0.37

Basham SA

20

3.089

0.206

20

3.795

0.206

Amalraj A (VAS 0–4)

15

2.91

0.36

15

2.65

0.459

Jäger R (200 mg)

21

0

0

21

0

0

Tanabe Y (pre)

8

0.833

0.625

8

1.04

0.94

Tanabe Y (post)

8

1.04

1.25

8

–

–

Tanabe Y scan (0–10) pre

10

0.676

0.795

10

0.636

0.477

Tanabe Y scan (0–10) post

10

0.954

1.113

10

1.193

1.113

Mallard AR (0–10)

13

0.375

0.625

14

0.375

0.5

Hillman AR

11

0.149

0.223

11

1.334

2.074

UMD (95% CI)

 − 0.12 (− 0.46, 0.22)

(b) VAS post-exercise

Nicol LM

17

2

1.5

17

1.75

1.75

Tanabe Y

14

1.36

1.48

14

1.42

1.59

Jäger R (50 mg)

–

2.97

1.73

21

–

–

Jäger R (200 mg)

21

2.14

0.99

21

2.97

1.81

Tanabe Y (pre)

8

1.04

0.833

8

1.56

1.87

Tanabe Y (post)

8

1.46

1.88

8

–

–

Tanabe Y scan (0–10) pre

10

0.795

0.795

10

1.113

2.385

Tanabe Y scan (0–10) post

10

1.431

1.67

10

1.749

1.749

Mallard AR (0–10)

13

3

2.5

14

2.5

2.25

Hillman AR

11

0.963

1.334

11

2.963

2.963

UMD (95%CI)

 − 0.38 (− 0.83, 0.08)

(c) VAS at 24 h

Nicol LM

17

2.87

1.33

17

3

2

Tanabe Y

14

4.32

2.5

14

4.77

1.82

McFarlin BK

14

3.53

0.32

14

4.84

0.63

Naknhostin-Roohi B

10

6.48

0.09

10

6.85

0.19

Jäger R (50 mg)

–

5.36

1.81

21

–

–

Jäger R (200 mg)

21

3.63

0.99

21

5.53

1.65

Tanabe Y (pre)

8

4.375

1.458

8

4.69

2.29

Tanabe Y (post)

8

3.44

1.46

8

–

–

Tanabe Y scan (0–10) pre

10

3.975

1.272

10

3.657

1.272

Tanabe Y scan (0–10) post

10

4.216

1.91

10

3.897

1.67

Mallard AR (0–10)

13

1.625

1.813

14

2.188

1.875

Hillman AR

11

2.667

1.778

11

4.667

3.482

UMD (95%CI)

 − 0.67 (− 1.19, − 0.16)

(d) VAS at 48 h

Drobnic F

9

2.33

0.79

10

3.06

7.9

Nicol LM

17

2.2

1.33

17

3.2

2.2

Tanabe Y

14

5.45

2.05

14

5.97

2.27

McFarlin BK

14

5.26

0.42

14

6.95

0.63

Naknhostin-Roohi B

10

6.67

0.19

10

8.33

0.19

Jäger R (50 mg)

–

4.289

1.98

21

–

–

Jäger R (200 mg)

21

3.88

0.99

21

4.289

2.23

Tanabe Y (pre)

8

7.083

1.667

8

5.94

2.6

Tanabe Y (post)

8

4.89

1.67

8

–

–

Tanabe Y scan (0–10) pre

10

6.519

0.954

10

5.724

1.272

Tanabe Y scan (0–10) post

10

5.408

1.83

10

6.208

1.67

Cardaci TD

11

4.66

1.58

12

6.12

1.58

Mallard AR (0–10)

13

0.813

0.876

14

1.25

0.875

Hillman AR

11

2.667

1.852

11

5.408

3.26

UMD (95% CI)

 − 0.86 (− 1.38, − 0.34)

(e) VAS at 72 h

Tanabe Y

14

4.66

2.5

14

5

2.5

McFarlin BK

14

1.89

0.42

14

3.89

0.63

Naknhostin-Roohi B

10

6.85

0.09

10

7.96

0.19

Basham SA

20

2.5

0.206

20

2.912

0.206

Jäger R (50 mg)

–

1.65

1.73

21

–

–

Jäger R (200 mg)

21

1.73

0.91

21

1.4

1.65

Tanabe Y (pre)

8

6.04

1.35

8

6.15

1.46

Tanabe Y (post)

8

4.06

1.25

8

–

–

Tanabe Y scan (0–10) pre

10

5.565

1.272

10

5.247

1.749

Tanabe Y scan (0–10) post

10

4.77

1.83

10

6.758

0.875

Mallard AR (0–10)

13

0.188

0.438

14

0.5

0.375

Hillman AR

11

1.112

1.186

11

4.445

3.112

UMD (95%CI)

 − 0.81 (− 1.27, − 0.36)

(f) VAS at 96 h

Tanabe Y

14

2.84

2.95

14

3.3

2.61

McFarlin BK

14

0.53

0.32

14

1.79

0.63

Amalraj A (VAS 0–4)

15

1.122

0.56

15

2.35

0.51

Tanabe Y (pre)

8

3.54

1.67

8

5.31

2.71

Tanabe Y (post)

8

3.33

1.88

8

–

–

Tanabe Y scan (0–10) pre

10

3.18

1.749

10

3.419

1.749

Tanabe Y scan (0–10) post

10

3.737

1.988

10

6.042

1.272

UMD (95%CI)

 − 1.24 (− 1.50, − 0.99)